化合物 T11518L
化合物 T11518L 性质
| 沸点 | 392.3±52.0 °C(Predicted) |
|---|---|
| 密度 | 1.30±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 形态 | 固体 |
| 酸度系数(pKa) | 2.22±0.10(Predicted) |
| 颜色 | 白色至米白色 |
| 水溶解性 | Water : ≥ 62 mg/mL (282.72 mM) |
化合物 T11518L 用途与合成方法
Kd: 40 nM (iNOS)IC50: 2.19 μM (human iNOS); 544 μM (human eNOS); 177 μM (human nNOS)ED50: 1.15 μM (rat iNOS); 252 μM (rat nNOS)
GW274150 inhibits intracellular iNOS in J774 cells in a time-dependent manner, reaching IC 50 values of 0.2 μM.GW274150 is >260-fold and 219-fold selective for iNOS against eNOS and nNOS in rat tissues, respectively. And it displays >100-fold and >80-fold for human iNOS against human eNOS and nNOS, respectively.
GW274150 is a long-acting (5 h half‐life in rats) iNOS inhibitor and is able to inhibit LPS‐mediated increase in plasma NO2 - , NO3 - levels 14 h after single intraperitoneal dose (ED 50 =3 mg/kg).GW274150 (intraperitoneal injection; 2.5, 5, and 10 mg/kg; before carrageenan injection) reduces the degree of lung injury induced by carrageenan in a dose-related fashion. Oedema formation and PMNs infiltration in the pleural cavity are also significantly attenuated in a dose‐related manner in rats.GW274150 (oral adminstration; 30 mg/kg; twice daily; 7 days) leads to significant neuroprotection, However, it displays a bell-shaped neuroprotective profile, being ineffective at high doses in 6-OHDA rat model of Parkinson disease (PD).
| Animal Model: | SD-rat |
| Dosage: | 2.5, 5 and 10 mg/kg; single dose |
| Administration: | Intraperitoneal injection 5 min before carrageenan injection |
| Result: | Exerted a protective role in an acute model of inflammation, carrageenan-induced lung injury. |
化合物 T11518L 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-12119 | 化合物 T11518L | 210354-22-6 | 5mg | 900 |
| 2024-11-08 | HY-12119 | 化合物 T11518L | 210354-22-6 | 10mM * 1mLin Water | 990 |
